



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**

**-or-**  
**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE:**

**DNAPRINT GENOMICS RECEIVES PATENT FOR IDENTIFYING LINKS BETWEEN GENE SEQUENCES AND MEDICAL TRAITS**

**SARASOTA, Fla., Sept. 19, 2006** – **DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that the Company's has formally been granted a patent by the U.S. Patent and Trademark Office for *Methods for the Identification of Genetic Features for Complex Genetics Classifiers*. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits), and follows a Notice of Allowance for the process that had been given to the Company in April of this year.

"It is important to protect the company's technologies and the revenue that can be derived from them," stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Our proprietary methods for marking gene sequences is especially important, because it is the key to developing theranostic drugs."

The patent provides legal protection for DNAPrint's status as one of a very few companies currently capable of performing objective, assumption-free haplotype, or analysis, of DNA strands. DNAPrint is also the only company currently using Ancestry Informative Markers (AIMs) and has patents pending in this area as well.

DNAPrint Genomics currently holds two other patents and has several others pending or in the hands of patent counsel.

**About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

(MORE)

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###

DNAG-PATENT.DOC